The CEO of the Year Awards Northeast USA 2025 .

---

OTI is Building a High-Standard Governance Platform

As OTI prepare for the next stage of growth, we are establishing a robust corporate governance framework—including policies, rules, and a compliance system—that will ensure OTI operates with transparency, fairness, and accountability. This foundation will provide investors and partners with confidence that contributions are safeguarded and aligned with value creation.

In support of this, OTI have appointed Hugh P. Cam, PhD, EMBA, as Vice President of Operations and Corporate Secretary (recordkeeping capacity). Hugh is Harvard trained human genetic expert, has worked with OTI since last April, brings scientific acumen, startup entrepreneurial and management experience from MIT, with EMBA on finance accouting proficiency, and will play a pivotal role in ensuring our compliance and operational readiness.

Looking Ahead

With breakthrough science and high-standard corporate governance, OTI is positioned to attract top-tier investors and world-class board members. Our mission remains clear: to deliver the first curative therapy for refractory glaucoma, addressing an urgent unmet need for patients and transforming a market that has seen little innovation in 30 years.

Advanced our pioneering science: “We pioneer MMP pathway–based therapy via tissue rejuvenation that can reverse tissue damage causing vision loss in patients with glaucoma. Like anti-VEGF for retina, it’s transformative medicine.” – Dr. Tina Guanting Qiu, Founder & CEO.

Dear Friends, Colleagues and Advisors,

I’m Dr. Tina Guanting Qiu, MD, PhD, Founder and CEO of Ophthalmic Therapeutic Innovation (OTI) LLC. I am an ophthalmic surgeon and stem cell transplant biologist with over 25 years in the field—including roles at GSK, Inotek, Astellas and Lineage Cell—I pioneer in big data for drug discovery and development (“do it faster, cheaper and better”). Today, I’m thrilled to invite you to join our equity crowdfunding campaign on Wefunder.

Glaucoma is the No.1 leading cause of irreversible blindness, projected to affect 120 million by 2040 worldwide. One in three patients risks legal blindness, there is no cure. Current standard of care (eye drop, surgeries and laser) is of symptom relief IOP lowering, temporarily. OTI is going to change this.

Unlike many startups still in early phases with only ideas and prototypes, OTI holds a patented, derisked, late stage, clinically validated Curative asset addressing a multi-billion-dollar market. We are currently raising a minimum of $250K (part of a $3-4M raise milestone) to fund critical IP/legal & SG&A cost to advance our candidate to pivotal Phase 3 trials.

OTI's clinical sciences are vetted by top glaucoma experts: Drs Louis Cantor, Ike Ahmed and James Tsai. OTI's regulatory strategy is aligned with new FDA Priorities at big data frontier.

We’re raising $3.0M via Wefunder to:
- IP/legal fees and SG&A costs ($250K).
- GMP materials and In vitro formulation stability testing.
- In vivo formulation validation & rabbit IOP study on bioequivalence (new formula vs Inotek’s eye drop formula).

Your investment—starting at $100—could unlock this visibility and propel us toward Phase 3 pivotal trials.

👉 Invest today or learn more: 

https://wefunder.com/ophthalmic.therapeutic.innovation.llc

📎 Our website: https://lnkd.in/ewk6HhRM
🔗 Phase 3 insights: https://lnkd.in/dyNmptsK

Thank you for believing in our mission.

With gratitude,
Tina Guanting Qiu, MD PhD EMBA
qiu-tina@ophthalmic-innovation.com

Disclaimers:
We are "testing the waters" to gauge investor interest in an offering under Regulation Crowdfunding. No money or other consideration is being solicited. If sent, it will not be accepted. No offer to buy securities will be accepted. No part of the purchase price will be received until a Form C is filed and only through Wefunder’s platform. Any indication of interest involves no obligation or commitment of any kind..

July 11th 2025, OTI has been selected to present at 2025 Future Ophthalmology Forum -Europeon Forum as Private Company Showcase at on September 11, 2025 at Copenhagan, Demark. Prior, OTI has been participating Future Ophthalmology Forum since 2021, and made presentations as Private Company  Showcase in 2023 European Forum at Vienna, Austria, and 2024 European Forum at Bacelona, Spain. Video recordings: https://www.ophthalmology-futures.com/past-forums/

June  17th, 2025, I had the pleasure to attend FDA commissioner hosted CEO Forums in Boston during 2025 BIO Convention, along with ~120 CEOs and executive leaders from Massachussetts and the NE region. My big takehome message from the new administration is FDA's Priorities at big data frontier, FDA encourages biotech Pharma to leverage big data real world evidence for regulatory submission, which helps to reduce costs and accelerate medicine innovation, focusing on curative (doi: 10.1001/jama.2025.10116). At the forum, I had a chance to share my views about the need for increasing the bar for drug efficacy scruitiny at early stage clinical development. Traditionally, as long as a drug is safe, FDA gives a green light. This has to change with increased big data and AI tools. We are very appreciative of this informative and direct dialogues with Dr. Marty A. Makary, M.D., M.P.H and sharing our concerns, feedback and suggestions. OTI's big data strategy is aligned with FDA's real word evidence policy, OTI is a pioneer in leveraging big data to solve the biggest problems - 90% failure in medicine development.

The 21st century ushers us into an information explosive era in modern medicine development. At the cusp of biology and technology convergences, medical breakthroughs sprout from the tiding waves of big data surge in this ever-changing modern world.  In this special  edition of MDG Boston roundtable discussions, we have invited our special guests, Professor Robert Langer at MIT, and Dr Janet Woodcock, former acting FDA commissioner, and Chris Cowles, IP Expert, Partner at Whither & Bergman to dive into some of the most exciting new frontiers where “big data”  is help shaping the future landscape of regulatory, IP, platform technology and more.  Watch the recordings:  https://www.mdgboston.org/event/the-extraordinary-impact-of-big-data-on-biomedical-innovation-platfo